Following a 70% retracement in XRP’s value from its all-time high, ChartNerd questioned the credibility of those still promoting unrealistic targets, specifically the $1,000 mark for the end of 2026.
XRP has fallen 70% from all time high, ChartNerd warns against $1,000 price calls
Critique of Unfounded Bullish Predictions
ChartNerd expressed skepticism over those still sharing posts predicting $1,000 for XRP within the year, stating he could “almost guarantee” such individuals paid little or no attention throughout XRP’s prolonged decline. He described these accounts as “probably 24/7 bullposting,” advising his followers to exercise caution when evaluating influencer commentary on social platforms.
He has maintained this critical stance throughout 2026, consistently challenging influencers and commentators who push extreme price targets after significant declines have already occurred. ChartNerd’s position has been clear: unrealistic price projections can have real financial consequences for retail investors who may act on such claims.
ChartNerd emphasized that many who promoted a $1,000 XRP price target appeared largely absent during the asset’s substantial downturn, and he urged followers to be discerning before acting on “bullposting” from influencer circles.
Ongoing Disagreement Among XRP Commentators
Despite persistent criticism, Dom Kwok, co-founder of EasyA and a prominent voice in the cryptocurrency sector, has reiterated his belief in a $1,000 target for XRP by year-end. Kwok has sustained his bullish forecast despite the asset’s steep drop in 2026, standing out as one of the few still backing such high projections.
Mini dictionary: EasyA is a Web3 education platform that provides blockchain learning modules and development tools for both beginners and experienced developers.
The debate among these figures has highlighted deep divisions in the XRP community about plausible price targets, especially after a major retrace from the peak.
Community Reactions and Realistic Expectations
Reactions from the wider XRP community on X have reflected a growing exhaustion with ambitious price predictions. One commenter suggested that ChartNerd remove the word “almost” from his guarantee, reflecting the sentiment that such optimistic voices are avoiding accountability amid falling prices.
Some community members are now aiming for more moderate targets. One said a price of $4 would be satisfactory given current conditions, while another predicted $2.50 for XRP by 2027. Another participant in the discussion stated he did not foresee XRP reaching $10 in the next cycle, setting $8 as his maximum expectation.
| $1,000 | Dom Kwok | Highly Bullish |
| $4 | X Community Member | Moderately Optimistic |
| $2.50 (2027) | X Community Member | Cautious |
| $8–10 | X Community Member | Conservative (Long-term) |
Other users advised conducting personal research rather than relying solely on influencer predictions. One participant noted that some advocates for the $1,000 price might actually exit the market at much lower price points and stated he intended to take profits at $10.
Within the XRP community, skepticism toward extreme price predictions has increased, with many participants instead adopting more conservative or methodical approaches to future expectations.
Earlier in 2026, ChartNerd also rejected claims that a gold revaluation could send XRP above $100,000, highlighting his consistent approach in challenging sensationalist targets in the cryptocurrency space.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Google Stock Climbs to $351.82 as Bullish Trend Faces a Key Test
StonkFun up 48% after integrating AAVE, AVAX – Can STONK reach $500M valuation?
RNA therapy company Adarx Pharmaceuticals (ADRX.US) plans to raise up to $372 million in a U.S. IPO; pharmaceutical giant AbbVie (ABBV.US) has agreed to invest up to $100 million
RNA therapy company Adarx Pharmaceuticals, which is in the late stage of clinical development, plans to raise up to $371.9 million through its initial public offering (IPO) in the United States.
